Investigation of CALML6 expression and its clinical relevance across pan-cancer.

Cancer is a major global health issue, leading to high morbidity and mortality. This study investigates CALML6 expression and its clinical relevance across cancer types using RNA-sequencing data from public databases like UCSC Xena and TCGA, assessing mRNA levels, mutations, CNV, SNV, methylation, and drug sensitivity via GSCA and cBioPortal. Results show CALML6 is upregulated in DLBC, LAML, and THYM, but downregulated in ACC, BRCA, and COAD. Survival analyses link CALML6 expression to DSS, OS, and PFI in ACC, COAD, and KIRC, suggesting its role as a prognostic biomarker. Immune infiltration analysis reveals positive associations with T effector memory and NK CD56bright cells, and negative correlations with immunosuppressive cells. Genetic analysis shows a positive link between CNV and CALML6 mRNA, while methylation and mutation counts are negatively associated. Drug sensitivity analysis indicated that CALML6 expression was correlated with the response patterns of several compounds, although the translational significance of these associations requires further validation. The relative expression levels represented by qRT-PCR validation showed that CALML6 expression was upregulated in BLCA, COAD, and STAD cell lines relative to the corresponding normal cell lines. In conclusion, this study supports the potential relevance of CALML6 as a prognostic biomarker candidate in pan-cancer. Further studies are warranted to validate its biological relevance experimentally and to assess its potential clinical significance in cancer.